RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test powerful new Immune-Boosting cocktail against tough ovarian cancers
Disease control Recruiting nowThis study is testing whether adding a new immune-stimulating drug (CDX-1140) to two existing cancer drugs works better for women whose ovarian cancer has returned. The goal is to see if this three-drug combination can shrink tumors more effectively, help patients live longer, an…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope: using a Patient's own supercharged cells to battle aggressive ovarian cancer
Disease control Recruiting nowThis early-stage study is testing a new personalized treatment for ovarian cancer that has returned or stopped responding to standard therapies. Doctors take a patient's own immune cells, grow and train them in a lab to recognize cancer, and then infuse them back into the patient…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat ovarian cancer: experimental drug trial opens
Disease control Recruiting nowThis early-stage study aims to find the safest and most effective dose of an experimental drug called DT2216 when given with standard chemotherapy (paclitaxel) for women with recurrent ovarian cancer that has stopped responding to platinum-based treatments. The trial will enroll …
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New Two-Punch combo tested for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis early-phase study is testing the safety and best dose of two oral drugs, abemaciclib and olaparib, given together for ovarian cancer that has returned and is resistant to standard platinum-based chemotherapy. The goal is to see if combining these drugs, which work in differe…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test new drug duo to target Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two oral drugs, M1774 and ZEN-3694, for women with recurrent ovarian or endometrial cancer. The main goals are to find the safest and most effective dose and to see how well the drugs work together to stop cancer cell growth.…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, pelcitoclax and cobimetinib, for women with ovarian or endometrial cancer that has returned after prior treatment. The main goals are to find the safest and most effective dose and to check for side effects. Resear…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC